Menlo Park, CA, United States of America

Thomas J Schall

This inventor holds 52 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 9 EPO patents, primarily in Chemokine Receptor Therapeutics. Top assignees: Chemocentryx, Inc., Schering Corporation, Amgen Inc.. Active years: 1991-2026.

USPTO Granted Patents = 52 (Patent Applications = 12)

% Patents Active = 80.8

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 4.2

ph-index = 8

Forward Citations = 279(Granted Patents)

Forward Citations (Not Self Cited) = 251(Dec 10, 2025)

Location History:

Meno Park, CA (US) (2006)
Palo Alto, CA (US) (1991 - 2014)
Menlo Park, CA (US) (2003 - 2023)
San Carlos, CA (US) (2006 - 2023)
Mountain View, CA (US) (2020 - 2024)

Company Filing History:

Leland Stanford Junior University

patents

where one patent can have more than one assignee

Years Active: 1991-2026

Loading Chart...

Areas of Expertise:

CCR2 Antagonist

PD-1 Inhibitor

Inflammatory Bowel Disease

Focal Segmental Glomerulosclerosis

Chemokine Receptor

Tumor Burden

Combination Therapy

CCX-CKR Modulators

Immune Response

Bis-Aryl Sulfonamides

CX3C Chemokines

TECK Polypeptides

52 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12734166 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies (2026-09-15),

2. 12611409 - Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor (2026-04-28),

3. 12194032 - Method of treating focal segmental glomerulosclerosis (2025-01-14),

4. 11883391 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-IL-23 blocking antibodies (2024-01-30),

5. 11844790 - Methods of treating hidradenitis suppurativa (2023-12-19),

6. 11744822 - Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors (2023-09-05),

7. 11382915 - Treatment of focal segmental glomerulosclerosis with CCR2 antagonists (2022-07-12),

8. 11324736 - Method of Treating Focal Segmental Glomerulosclerosis (2022-05-10),

9. 11304952 - Combination therapy using a chemokine receptor 2 (CCR2) antagonist and a PD-1/PD-L1 inhibitor (2022-04-19),

10. 11045469 - Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies (2021-06-29),

11. 11020394 - Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-α4β7 integrin blocking antibodies (2021-06-01),

12. 10973809 - Method of treating focal segmental glomerulosclerosis (2021-04-13),

13. 10792360 - Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies (2020-10-06),

14. 10758540 - Treatment of focal segmental glomerulosclerosis with CCR2 antagonists (2020-09-01),

15. 10568870 - Reducing tumor burden by administering CCR1 antagonists in combination with PD-1 inhibitors or PD-L1 inhibitors (2020-02-25),

Title: The Innovative Mind of Thomas J Schall

Introduction: Thomas J Schall, a talented inventor based in Menlo Park, CA, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents: Thomas J Schall holds several patents in various technological domains, including artificial intelligence, renewable energy, and medical devices.

Career Highlights: With a career spanning over two decades, Thomas J Schall has worked for renowned tech companies, leading research institutions, and innovative startups, where he has been instrumental in developing cutting-edge technologies.

Collaborations: Throughout his career, Thomas J Schall has collaborated with top engineers, scientists, and researchers from around the world, fostering a culture of innovation and excellence in all his projects.

Conclusion: Thomas J Schall's passion for innovation and his relentless pursuit of technological advancement continue to inspire the next generation of inventors and entrepreneurs.